MMDS future plans include development of manufacturing facilities in Europe for worldwide distribution of TETRACAN to jurisdictions which accept TETRACAN as a holistic, therapeutic adjunctive for management of chronic pain due to arthritis, the side effects of chemotherapy, multiple sclerosis and other chronic conditions.